ArticleFrontiers in oncology2019

Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated Multidrug Resistance in Cancer Cells.

Qingbin Cui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.